Search Results 2141-2150 of 17106 for Green Birth Control

  1. Medical Research & Education - Mayo Clinic News Network

    ROCHESTER, Minn. — Mayo Clinic researchers have developed a new artificial intelligence (AI) tool that helps clinicians identify brain activity patterns linked ...

  2. Targeted Muscle Reinnervation and Prosthetics Function: The Mayo Clinic Experience

    To compare outcomes with other procedures for prosthetic control improvement. Participation eligibility. Participant eligibility includes age, gender, type ...

  3. Colorectal cancer cases rising in younger adults, screenings are down - Mayo Clinic News Network

    Lisa Boardman, a Mayo Clinic gastroenterologist. "We used to think of colorectal cancer as a disease of aging. With the increase in the number of cases of ...

  4. A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies - Mayo Clinic

    Patients in the study will be treated with Melphalan/HDS and will receive up to 6 total treatments. This study will evaluate the safety and effects of the ...

  5. A Trial Investigating the Safety, Tolerability and Efficacy of TransCon PTH in Adults With Hypoparathyroidism - Mayo Clinic

    About this study. To assess the effectiveness of daily TransCon PTH on serum and calcium levels and active vitamin D and calcium doses at 4 weeks of ...

  6. Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia - Mayo Clinic

    Zidovudine is not allowed as part of the anti-HIV therapy. Patients with diabetes controlled by diet or medication are allowed on trial; controlled diabetes ...

  7. Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES) - Mayo Clinic

    Mepolizumab is a humanized monoclonal antibody. ... This is a 32-week treatment period, randomized, double-blind, placebo-controlled, parallel group, multicentre ...

  8. Mayo Clinic Minute - 2016 Archives

    As we prepare for the New Year, we salute the past 12 months. During this time, the Mayo Clinic News Network team has brought a number[...].

  9. A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer - Mayo Clinic

    A Phase Ⅲ Study Of Rilvegostomig In Combination With Fluoropyrimidine And Trastuzumab Deruxtecan As The First-line Treatment For HER2-positive Gastric Cancer.

  10. Blood, Corneal Endothelial and Skin Cell Repository for Research on Fuchs Endothelial Corneal Dystrophy at Mayo Clinic Florida - Mayo Clinic

    Patients scheduled for endothelial keratoplasty surgery for non-FECD indications as controls for the study. Exclusion Criteria: Limited mental capacity ...